Molecular target of anticancer drug resistant ovarian cancer: EMT transcription factor ZEB1

Research Project

Project/Area Number	18K16795
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 56040:Obstetrics and gynecology-related
Research Institution	Aichi Cancer Center Research Institute
Principal Investigator	Sakata Jun 愛知県がんセンター(研究所), がん予防研究分野, 研究員 (40778297)
Project Period (FY)	2018-04-01 – 2022-03-31
Project Status	Completed (Fiscal Year 2021)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords	再発卵巣癌 / 抗癌剤耐性 / drug rechallenge / 卵巣癌 / 抗癌剤耐性卵巣癌 / 結合組織成長因子（CTGF） / EMT転写因子ZEB1 / classⅠHDAC阻害剤 / CTGF / 薬剤耐性
Outline of Final Research Achievements	In this study, EMT transcription factor ZEB1 and binding tissue growth factor CTGF are involved in anticancer drug resistance and metastatic infiltration as targets for the treatment of refractory recurrent ovarian cancer, and have been investigated as new therapeutic targets for refractory ovarian cancer in the future. ZEB1 and CTGF play a central role in both chemotherapy resistance and metastatic capacity of epithelial ovarian cancer, and high expression of each of ZEB1 and CTGF has poor clinical outcomes in patients with epithelial ovarian cancer. It has been shown to be a valuable predictor. The mutual involvement of TGF-β and ZEB1 / CTGF was clarified, and its importance as a therapeutic target for ovarian cancer was further verified.
Academic Significance and Societal Importance of the Research Achievements	卵巣癌治療において、抗癌剤耐性の獲得は予後に影響する重大な因子であり、本研究では難治性再発卵巣癌治療の標的として、ZEB1やCTGFの関与についてすでに論文で報告済みである。